No adverse safety or virological changes 2 years following vorinostat in HIV-infected individuals on antiretroviral therapy
Talia M Mota, Thomas A Rasmussen, Ajantha Rhodes, Surekha Tennakoon, Ashanti Dantanarayana, Fiona Wightman, Michelle Hagenauer, Janine Roney, Tim Spelman, Damian FJ Purcell, James McMahon, Jennifer F Hoy, H Miles Prince, Julian H Elliott, Sharon R Lewin
AIDS | LIPPINCOTT WILLIAMS & WILKINS | Published : 2017
Awarded by National Institutes for Health
Awarded by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
The work was supported by an investigator initiated grant from Merck. Other sources of support included the National Health and Medical Research Council (NHMRC) of Australia and the National Institutes for Health U19 AI096109. SRL is an NHMRC Practitioner Fellow.